Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 64 references it cites were found in a registry or an index; 56 of the 75 sources its claims cite were checked for support.

Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer

Open access
Rubio-Cuesta, Beatriz, Carretero-Puche, Carlos, Llamas, Patricia, Sarmentero, Jacinto, Gil-Calderon, Beatriz, Lens-Pardo, Alberto, Antón-Pascual, Beatriz, Rubio-González, Eduardo, Cámara-Jurado, María, Salamanca, Javier, Rueda-Fernández, Daniel, Delcuratolo, Marco Donatello, Soldevilla, Beatriz, Garcia-Carbonero, Rocio · 2025 · British Journal of Cancer

Abstract

Background: BRAF V600E mutations occur in ∼10% of colorectal cancer (CRC) patients, leading to poor prognosis. Although BRAF-targeted therapy is ineffective in CRC, adding EGFR inhibitors (EGFRi) improves efficacy, yet patient survival remains suboptimal. This study explores SRC as a key mediator of resistance to BRAF inhibitors (BRAFi) in preclinical BRAF V600E CRC models, and its potential as a therapeutic target. Methods: We studied SRC using BRAF-mutated and wild-type CRC cell lines with CRISPR/Cas9 knockouts and lentiviral overexpression. We tested SRC, BRAF, EGFR, and JNK targeting drugs, assessing protein expression, cell viability, proliferation, migration, apoptosis, and cell cycle. CRC cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models were established for in vivo studies. Results: SRC regulates proliferation, clonogenicity, migration and mediates BRAFi resistance in BRAF V600E CRC, regardless of microsatellite instability. Depletion or inhibition of SRC sensitized cells to BRAFi. Combined SRC and BRAF inhibition demonstrated a synergistic antitumor effect, reducing cell viability and inducing apoptosis and cell cycle arrest in cell lines and PDXs. The JNK/c-Jun pathway contributes to adaptive resistance, and its inhibition enhances the effects of dual SRC and BRAF inhibition. Conclusions: These findings identify new therapeutic targets for clinical trials, potentially improving outcomes for this high-risk CRC subgroup.

Overview

CoChat Summary

TL;DR

This preclinical study identifies SRC as a mediator of resistance to BRAF inhibitors in BRAFV600E colorectal cancer and shows that co-targeting SRC with dasatinib plus BRAF inhibitors is synergistic in vitro and in vivo. It also implicates JNK/c-JUN signaling in adaptive resistance to dual SRC/BRAF inhibition.

Key findings

  • SRC modulated oncogenic capacities in BRAFV600E CRC: overexpression promoted proliferation, migration, and colony formation and produced larger xenograft tumors, while SRC depletion reduced growth, migration, and colonies. BRAF inhibition upregulated pSRC; in HT29 cells, SRC overexpression increased BRAFi IC50 values up to five times, and SRC knockout lowered them four times versus controls.
  • Dual SRC and BRAF inhibition was synergistic by Chou-Talalay analysis (CI < 0.9) and reduced cell viability, colony formation, and migration, while increasing apoptosis and G0/G1 cell cycle arrest in BRAFV600E CRC cell lines.
  • In HT29 CDX and two PDX models, combined SRCi plus BRAFi produced significantly smaller tumors than monotherapies or vehicle. In PDX #2, encorafenib plus dasatinib, encorafenib plus cetuximab, and the triplet encorafenib/cetuximab/dasatinib all improved tumor growth inhibition versus vehicle and monotherapies, but the triplet was not significantly different from dual BRAF/EGFR or BRAF/SRC inhibition.
  • c-JUN phosphorylation increased after dual SRC/BRAF inhibition; JNK inhibition reduced growth and increased apoptosis, c-JUN overexpression decreased apoptosis, and JNK inhibition enhanced apoptosis induced by dual SRC/BRAF targeting. The paper reports the combination effect was independent of microsatellite instability status across CDX (MSS) and PDX (MSI) models.

Methods

  • BRAFV600E CRC cell lines (HT29, SW1417, WiDr, LS411N, RKO) and RAS/BRAF WT DIFI cells were used; SRC was knocked out by CRISPR/Cas9 or overexpressed lentivirally, and c-JUN was transiently overexpressed.
  • Drugs tested included vemurafenib, encorafenib, dasatinib, cetuximab, and JNK inhibitor SP600125. Assays included Western blotting, phospho-kinase array, cell viability, Chou-Talalay synergy, proliferation, transwell migration, colony formation, and flow cytometry for apoptosis and cell cycle.
  • In vivo studies used HT29 cell line-derived xenografts and two patient-derived xenografts in female athymic nude mice; tumors were molecularly characterized for KRAS/NRAS/BRAF and MSI/dMMR. Statistics used two-sided unpaired Student’s t tests or Mann–Whitney U tests, with P < 0.05 considered significant.

Limitations

  • The paper states that dasatinib also inhibits other kinases including c-KIT, PDGFRβ, and EPHA2, so non-specific effects beyond SRC inhibition cannot be ruled out; it also notes that ATP-competitive inhibitors such as dasatinib can paradoxically activate SRC/ERK, and pERK increased in some dasatinib-treated mice.
  • The paper states that data collection and analysis were not blinded, and that data distribution was assumed homoscedastic but not always formally tested; it also states that mechanisms of the observed synergism remain to be elucidated.
  • Evident from the text: all efficacy findings are preclinical, using cell lines and mouse CDX/PDX models, with no clinical trial or patient outcome data; in vivo group sizes were small (for example, n = 4–9 per group in PDX experiments).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41416-025-03058-6

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 SRC is activated following BRAF inhibition in BRAFm CRC cell lines and efficiently inhibited by dasatinib. a On the left, proteome human phospho-kinase array of HT29 cell line following vemurafenib treatment (IC50 value, 24 h). The black boxes in the figure highlight pSRC (Y419) upregulation, and the pixel densitometry representation of this data is shown below. On the right, expression of SRC and pSRC in the panel of CRC BRAFV600E cell lines treated with BRAFi (vemurafenib (HT29, SW1417 and WiDr) or encorafenib (LS411N and RKO)) at their IC50 values for 8 h. SRC activation is reflected by increased phosphorylation of the SRC activation site Y419 (pY419). β-actin used as a loading control. Molecular weight/size markers are indicated on the right (kDa). Images of WB are representative of 3 independent experiments. b Dose-response curves of HT29 cells (SRC OE and SRC KO cells) after treatment with vemurafenib or encorafenib for 72 h (left). On the right, representation of IC50 values of modified HT29 cells after treatment with vemurafenib or encorafenib for 72 h, compared to controls. Data represent the mean ± SEM of at least 3 biologically independent experiments. c Representative WB analysis of pSRC and SRC in HT29 cells after being treated at different concentrations (0.2–2 µM) for 24 h and with 1.2 µM dasatinib at the indicated time points (1–24 h), and their respective controls. β-actin used as a loading control. Data are representative of 3 independent experiments. Protein quantification is shown below as a pSRC/SRC ratio. d Dose-response assay of HT29 treated with dasatinib for 72 h, after treatment with the IC20 (0.06 µM), IC50 (1.20 µM) and IC70 (4.11 µM) doses (n = 3 replicates examined). e Transwell assay for cell migration in HT29 cells after being treated with dasatinib or control (DMSO) for 24 h. Transmigrated cells were quantified by cell titter. Error bars represent the mean ± SD of 4 biologically independent experiments. Significance was considered for *P < 0.05, **P < 0.01 and ***P < 0.001. D dasatinib, IC20 20% inhibitory concentration, IC50, half-maximal inhibitory concentration, IC70 70% inhibitory concentration, CTRL control, OE overexpression, KO knock-out.
Fig. 1 SRC is activated following BRAF inhibition in BRAFm CRC cell lines and efficiently inhibited by dasatinib. a On the left, proteome human phospho-kinase array of HT29 cell line following vemurafenib treatment (IC50 value, 24 h). The black boxes in the figure highlight pSRC (Y419) upregulation, and the pixel densitometry representation of this data is shown below. On the right, expression of SRC and pSRC in the panel of CRC BRAFV600E cell lines treated with BRAFi (vemurafenib (HT29, SW1417 and WiDr) or encorafenib (LS411N and RKO)) at their IC50 values for 8 h. SRC activation is reflected by increased phosphorylation of the SRC activation site Y419 (pY419). β-actin used as a loading control. Molecular weight/size markers are indicated on the right (kDa). Images of WB are representative of 3 independent experiments. b Dose-response curves of HT29 cells (SRC OE and SRC KO cells) after treatment with vemurafenib or encorafenib for 72 h (left). On the right, representation of IC50 values of modified HT29 cells after treatment with vemurafenib or encorafenib for 72 h, compared to controls. Data represent the mean ± SEM of at least 3 biologically independent experiments. c Representative WB analysis of pSRC and SRC in HT29 cells after being treated at different concentrations (0.2–2 µM) for 24 h and with 1.2 µM dasatinib at the indicated time points (1–24 h), and their respective controls. β-actin used as a loading control. Data are representative of 3 independent experiments. Protein quantification is shown below as a pSRC/SRC ratio. d Dose-response assay of HT29 treated with dasatinib for 72 h, after treatment with the IC20 (0.06 µM), IC50 (1.20 µM) and IC70 (4.11 µM) doses (n = 3 replicates examined). e Transwell assay for cell migration in HT29 cells after being treated with dasatinib or control (DMSO) for 24 h. Transmigrated cells were quantified by cell titter. Error bars represent the mean ± SD of 4 biologically independent experiments. Significance was considered for *P < 0.05, **P < 0.01 and ***P < 0.001. D dasatinib, IC20 20% inhibitory concentration, IC50, half-maximal inhibitory concentration, IC70 70% inhibitory concentration, CTRL control, OE overexpression, KO knock-out.CC BY · PubMed Central
Fig. 2 Synergistic interaction of SRCi and BRAFi in MSS BRAFm CRC. a Cell viability after a 72 h treatment with IC50 values of SRCi (dasatinib), BRAFi (vemurafenib and encorafenib) and the combination of both in HT29 cell line. Error bars represent the mean ± SEM of 3 biologically independent experiments. Below, representative images under light microscope of cell viability after 48 h of the indicated treatments. Scale bar, 200 µm. b Heatmaps of cell viability assays for the combination of increasing concentrations of the drugs after data normalization in 0–100 scale. 0 means strong cell killing. c Selected concentrations of BRAFi and SRCi with the CI value, obtained with compusyn software. CI < 0.9 means synergy. Significance was considered for *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. V vemurafenib, E encorafenib, D dasatinib, CI combination index.
Fig. 2 Synergistic interaction of SRCi and BRAFi in MSS BRAFm CRC. a Cell viability after a 72 h treatment with IC50 values of SRCi (dasatinib), BRAFi (vemurafenib and encorafenib) and the combination of both in HT29 cell line. Error bars represent the mean ± SEM of 3 biologically independent experiments. Below, representative images under light microscope of cell viability after 48 h of the indicated treatments. Scale bar, 200 µm. b Heatmaps of cell viability assays for the combination of increasing concentrations of the drugs after data normalization in 0–100 scale. 0 means strong cell killing. c Selected concentrations of BRAFi and SRCi with the CI value, obtained with compusyn software. CI < 0.9 means synergy. Significance was considered for *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. V vemurafenib, E encorafenib, D dasatinib, CI combination index.CC BY · PubMed Central
Fig. 3 Dual SRC and BRAF inhibition leads to a reduction in cell clonogenicity and migration in BRAFm CRC cell lines. CFAs for HT29 (a), SW1417 (b), WiDr (c) and RKO (d) cell lines. Drug doses: V (0.14, 0.08, 0.08, 0.60 (μM)), E (0.08, 0.03, 0.05, 0.016 (μM)), D (0.10, 0.001, 0.003, 0.10 (μM)). Left graphs represent the quantification of the area and intensity of the colonies after treatment with SRCi (dasatinib) plus BRAFi (vemurafenib, left) or BRAFi (encorafenib, right), as well as their respective controls (vehicle, BRAFi and SRCi in monotherapy). Data represent the mean ± SEM of 3 biologically independent experiments. Below the graphs, representative images of the colonies after crystal violet staining. On the right, transwell assay for cell migration in HT29 (e), SW1417 (f), WiDr (g) and RKO (h) cell lines. Drug doses: V (0.40, 0.08, 0.08, 1.850 (μM)), E (0.08, 0.005, 0.008, 0.016 (μM)), D (0.10, 0.001, 0.003, 0.10 (μM)). Transmigrated cells were quantified by cell titter relative to control. Data represent the mean ± SEM of 3 biologically independent experiments. Asterisk above the bar indicates significance between that groups versus the control, square brackets indicate it for the pointed groups. Significance was considered for *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. V vemurafenib, E encorafenib, D dasatinib.
Fig. 3 Dual SRC and BRAF inhibition leads to a reduction in cell clonogenicity and migration in BRAFm CRC cell lines. CFAs for HT29 (a), SW1417 (b), WiDr (c) and RKO (d) cell lines. Drug doses: V (0.14, 0.08, 0.08, 0.60 (μM)), E (0.08, 0.03, 0.05, 0.016 (μM)), D (0.10, 0.001, 0.003, 0.10 (μM)). Left graphs represent the quantification of the area and intensity of the colonies after treatment with SRCi (dasatinib) plus BRAFi (vemurafenib, left) or BRAFi (encorafenib, right), as well as their respective controls (vehicle, BRAFi and SRCi in monotherapy). Data represent the mean ± SEM of 3 biologically independent experiments. Below the graphs, representative images of the colonies after crystal violet staining. On the right, transwell assay for cell migration in HT29 (e), SW1417 (f), WiDr (g) and RKO (h) cell lines. Drug doses: V (0.40, 0.08, 0.08, 1.850 (μM)), E (0.08, 0.005, 0.008, 0.016 (μM)), D (0.10, 0.001, 0.003, 0.10 (μM)). Transmigrated cells were quantified by cell titter relative to control. Data represent the mean ± SEM of 3 biologically independent experiments. Asterisk above the bar indicates significance between that groups versus the control, square brackets indicate it for the pointed groups. Significance was considered for *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. V vemurafenib, E encorafenib, D dasatinib.CC BY · PubMed Central
Fig. 4 SRCi plus BRAFi promotes apoptosis and cell cycle arrest in BRAFm CRC cells. Representative apoptotic profiles of Annexin V-APC/7-AAD staining of HT29 (a), WiDr (b), LS411N (c) and RKO (d) cell lines after the indicated treatments V (0.40, 1.50, 0.35, 1.85 (μM)), E (0.08, 2.00, 0.001, 2.00 (μM)), D (0.10, 0.03, 0.10, 0.10 (μM))) for 48 h. Below, histogram representation showing apoptotic rates. Mean and SD of 5 independent experiments are shown. Significance was considered for *P < 0.05, **P < 0.01, ***P < 0.001. Representative images of cell cycle distribution of HT29 (e), WiDr (f), LS411N (g) and RKO (h) cell lines after the indicated treatments (V (0.40, 0.10, 2.10, 1.85 (μM)), E (0.08, 0.30, 0.37, 0.60 (μM)), D (0.10, 0.02, 0.10, 0.10 (μM))) of one representative replicate are shown. Below, a bar diagram representation shows the percentage of G0/G1, S and G2 cells in each condition, showing mean ± SD of at least 3 biologically independent experiments. Asterisk above the bar means significance between that groups versus the control (DMSO), square brackets indicate it for the pointed groups. Significance is shown for S phase, considered for * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. NT non-treated, PI Propidium iodide, NT non-treated, V vemurafenib, E encorafenib, D dasatinib.
Fig. 4 SRCi plus BRAFi promotes apoptosis and cell cycle arrest in BRAFm CRC cells. Representative apoptotic profiles of Annexin V-APC/7-AAD staining of HT29 (a), WiDr (b), LS411N (c) and RKO (d) cell lines after the indicated treatments V (0.40, 1.50, 0.35, 1.85 (μM)), E (0.08, 2.00, 0.001, 2.00 (μM)), D (0.10, 0.03, 0.10, 0.10 (μM))) for 48 h. Below, histogram representation showing apoptotic rates. Mean and SD of 5 independent experiments are shown. Significance was considered for *P < 0.05, **P < 0.01, ***P < 0.001. Representative images of cell cycle distribution of HT29 (e), WiDr (f), LS411N (g) and RKO (h) cell lines after the indicated treatments (V (0.40, 0.10, 2.10, 1.85 (μM)), E (0.08, 0.30, 0.37, 0.60 (μM)), D (0.10, 0.02, 0.10, 0.10 (μM))) of one representative replicate are shown. Below, a bar diagram representation shows the percentage of G0/G1, S and G2 cells in each condition, showing mean ± SD of at least 3 biologically independent experiments. Asterisk above the bar means significance between that groups versus the control (DMSO), square brackets indicate it for the pointed groups. Significance is shown for S phase, considered for * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. NT non-treated, PI Propidium iodide, NT non-treated, V vemurafenib, E encorafenib, D dasatinib.CC BY · PubMed Central
Fig. 5 Role of c-JUN on cell survival in BRAFm CRC cell lines. a Scanned membranes of the proteome human phospho-kinase array revealed upregulation of c-JUN in HT29 cell line after dual inhibition of SRC and BRAF. On the right, graphical representation of the pixel density quantification of the membranes using scanned images from Image Quant TL software. b Representative WB analysis of phosphorylated and total JUN in HT29 cell line after the indicated treatments. Images of WB are representative of 3 independent experiments. β-actin was used as a loading control. Molecular weight/size markers are indicated on the right (kDa). pJUN/JUN ratio is shown below. c BRAFV600E CRC cell lines were treated with JNKi (SP600125) or with the vehicle (CTRL) for 24 h, and cell viability relative to control and apoptosis were measured by crystal violet or by Annexin V-APC/7-AAD staining by flow cytometry, respectively. Mean and SEM of 3 independent experiments are shown. d BRAFV600E CRC cell lines were transiently transfected with OE JUN plasmid or control plasmid (CTRL), and cell viability relative to control and apoptosis were measured by crystal violet or by Annexin V-APC/7-AAD staining by flow cytometry, respectively. Average and SEM of 3 independent experiments are shown. Flow cytometry analysis measured by Annexin V-APC/7-AAD staining of HT29 after treatment with JNKi (e) or after c-JUN overexpression (f); compared to control cells, and following the indicated treatments for 24 h (n = 5). Mean and SEM of 3 independent experiments are shown. Significance was considered for *P < 0.05, **P < 0.01 and ***P < 0.001. Ns non-significant, CTRL control, OE overexpression of c-JUN, JNKi JNK inhibitor (30 µM), DM DMSO, V vemurafenib, E encorafenib, D dasatinib.
Fig. 5 Role of c-JUN on cell survival in BRAFm CRC cell lines. a Scanned membranes of the proteome human phospho-kinase array revealed upregulation of c-JUN in HT29 cell line after dual inhibition of SRC and BRAF. On the right, graphical representation of the pixel density quantification of the membranes using scanned images from Image Quant TL software. b Representative WB analysis of phosphorylated and total JUN in HT29 cell line after the indicated treatments. Images of WB are representative of 3 independent experiments. β-actin was used as a loading control. Molecular weight/size markers are indicated on the right (kDa). pJUN/JUN ratio is shown below. c BRAFV600E CRC cell lines were treated with JNKi (SP600125) or with the vehicle (CTRL) for 24 h, and cell viability relative to control and apoptosis were measured by crystal violet or by Annexin V-APC/7-AAD staining by flow cytometry, respectively. Mean and SEM of 3 independent experiments are shown. d BRAFV600E CRC cell lines were transiently transfected with OE JUN plasmid or control plasmid (CTRL), and cell viability relative to control and apoptosis were measured by crystal violet or by Annexin V-APC/7-AAD staining by flow cytometry, respectively. Average and SEM of 3 independent experiments are shown. Flow cytometry analysis measured by Annexin V-APC/7-AAD staining of HT29 after treatment with JNKi (e) or after c-JUN overexpression (f); compared to control cells, and following the indicated treatments for 24 h (n = 5). Mean and SEM of 3 independent experiments are shown. Significance was considered for *P < 0.05, **P < 0.01 and ***P < 0.001. Ns non-significant, CTRL control, OE overexpression of c-JUN, JNKi JNK inhibitor (30 µM), DM DMSO, V vemurafenib, E encorafenib, D dasatinib.CC BY · PubMed Central
Fig. 6 Inhibition of SRC and BRAFV600E reduces tumor growth in BRAFm CRC in vivo CDX models. a HT29 CDX models after treatment with single agent SRCi dasatinib, BRAF inhibitor vemurafenib or their combinations with SRC inhibitor (n = 6 mice per group, except NT (n = 7)). b HT29 CDX models after treatment with single agent SRCi dasatinib, BRAF inhibitor encorafenib or their combinations with SRC inhibitor (n = 7 mice per group; except, E + D (n = 6)). c BRAFm CRC PDX #1 treated with vehicle (VEH, control, n = 9), vemurafenib (n = 7), dasatinib (n = 7), vemurafenib and dasatinib (n = 8). d PDX #2 treated with vehicle (VEH, control, n = 6), encorafenib (n = 5), dasatinib (n = 5), cetuximab (n = 4), encorafenib and cetuximab (n = 6), encorafenib and dasatinib (n = 7), and the triplet combination of encorafenib, cetuximab and dasatinib (n = 7). Graphs represent: tumor volumes determined at indicated time points after treatments and last day tumor weight. Image of one representative tumor for each group after finishing the treatment were also shown. Data are represented as the mean ± SEM. Significance was considered for *P < 0.05, *P < 0.01 and **P < 0.001. NT non-treated, VEH vehicle, V vemurafenib, E encorafenib, D dasatinib, C cetuximab.
Fig. 6 Inhibition of SRC and BRAFV600E reduces tumor growth in BRAFm CRC in vivo CDX models. a HT29 CDX models after treatment with single agent SRCi dasatinib, BRAF inhibitor vemurafenib or their combinations with SRC inhibitor (n = 6 mice per group, except NT (n = 7)). b HT29 CDX models after treatment with single agent SRCi dasatinib, BRAF inhibitor encorafenib or their combinations with SRC inhibitor (n = 7 mice per group; except, E + D (n = 6)). c BRAFm CRC PDX #1 treated with vehicle (VEH, control, n = 9), vemurafenib (n = 7), dasatinib (n = 7), vemurafenib and dasatinib (n = 8). d PDX #2 treated with vehicle (VEH, control, n = 6), encorafenib (n = 5), dasatinib (n = 5), cetuximab (n = 4), encorafenib and cetuximab (n = 6), encorafenib and dasatinib (n = 7), and the triplet combination of encorafenib, cetuximab and dasatinib (n = 7). Graphs represent: tumor volumes determined at indicated time points after treatments and last day tumor weight. Image of one representative tumor for each group after finishing the treatment were also shown. Data are represented as the mean ± SEM. Significance was considered for *P < 0.05, *P < 0.01 and **P < 0.001. NT non-treated, VEH vehicle, V vemurafenib, E encorafenib, D dasatinib, C cetuximab.CC BY · PubMed Central

Verification

Claims the paper makes

27 Valid · 0 Not valid · 3 Not checked · 83 Own results and interpretations

68 more claims · 6 with their cited sources checked

Create a free account to see all 113 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 21
  • It may state two separate claims as one. 25
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 64 references

Cited by

See all 7

Metadata

Authors
Rubio-Cuesta, B., Carretero-Puche, C., Llamas, P., Sarmentero, J., Gil-Calderon, B., Lens-Pardo, A., Antón-Pascual, B., Rubio-González, E., Cámara-Jurado, M., Salamanca, J., Rueda-Fernández, D., Delcuratolo, M. D., Soldevilla, B., & Garcia-Carbonero, R.
Affiliations
  • Research Institute Hospital 12 de Octubre (ES)
  • Hospital Universitario 12 De Octubre (ES)
Corresponding author
Soldevilla, Beatriz
Venue
British Journal of Cancer
Published
2025-06-06
Volume
133
Issue
3
Pages
404-419
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W4411089286
Cited by
7
References
64
Citations by year
2026: 4 · 2025: 3
FWCI
2.88
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Fundación Científica Asociación Española Contra el Cáncer (POSTDO46SOLD)
  • Comunidad de Madrid (PEJD-2017-PRE/BMD-4981, PEJD-2016-PRE/BMD-2666)
  • Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PFIS; FI20/00131, PI16-01827, PI19-01583)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
Src kinase, BRAF V600E mutation, colorectal cancer, BRAF inhibitor resistance, EGFR inhibitors, JNK/c-Jun pathway, combination therapy, adaptive resistance, apoptosis, cell cycle arrest, microsatellite instability, patient-derived xenografts
MeSH terms
Animals, Cell Movement, Female, Humans, Mutation, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, src-Family Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer. https://app.cochat.ai/papers/10.1038/s41416-025-03058-6
The paper
Rubio-Cuesta, B., Carretero-Puche, C., Llamas, P., Sarmentero, J., Gil-Calderon, B., Lens-Pardo, A., Antón-Pascual, B., Rubio-González, E., Cámara-Jurado, M., Salamanca, J., Rueda-Fernández, D., Delcuratolo, M. D., Soldevilla, B., & Garcia-Carbonero, R. (2025). Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-025-03058-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.